Analysis of boron neutron capture reaction sensitivity using Monte Carlo simulation and proposal of a new dosimetry index in boron neutron capture therapy.
Monte Carlo simulation
absolute biological effectiveness (ABE)
boron neutron capture therapy (BNCT)
compound biological effectiveness (CBE)
dosimetry index
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
21 Sep 2022
21 Sep 2022
Historique:
received:
14
02
2022
revised:
26
04
2022
pubmed:
7
7
2022
medline:
24
9
2022
entrez:
6
7
2022
Statut:
ppublish
Résumé
Boron neutron capture therapy is a cellular-scale heavy-particle therapy. The factor determining the biological effects in the boron neutron capture reaction (BNCR) is the value of ${\alpha}_{boron}$, which is the alpha component in the Linear Quadratic (LQ) model. Recently, the factor determining the value of ${\alpha}_{boron}$ has been revealed to correspond to the structural features of the tumor tissue. However, the relationship and mechanism have yet to be thoroughly studied. In this study, we simulated BNCR in tissues using the Monte Carlo simulation technique and examined the factors that determine the value of ${\alpha}_{boron}$. According to this simulation, the nuclear-cytoplasmic (N/C) ratio, nuclear diameter and heterogeneity of the distribution of boron in the tissue have been suggested to determine the value of ${\alpha}_{boron}$. Moreover, we proposed Biological Effectivity (BE) as a new dosimetry index based on the surviving fraction (SF), extending the concept of absolute biological effectiveness (ABE) in a previous report.
Identifiants
pubmed: 35791445
pii: 6631441
doi: 10.1093/jrr/rrac038
pmc: PMC9494546
doi:
Substances chimiques
Boron
N9E3X5056Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780-791Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
Références
J Radiat Res. 2018 Mar 1;59(2):122-128
pubmed: 29315429
Radiat Res. 2014 Oct;182(4):408-19
pubmed: 25229975
Appl Radiat Isot. 2020 Jul;161:109159
pubmed: 32250845
Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1081-6
pubmed: 8600091
Org Biomol Chem. 2015 Jul 7;13(25):6927-30
pubmed: 26022725
J Radiat Res. 2009 Mar;50 Suppl A:A59-65
pubmed: 19346686
Radiat Res. 2012 Dec;178(6):609-21
pubmed: 23148506
Radiat Res. 1987 Jul;111(1):14-25
pubmed: 3602351
Radiother Oncol. 1994 Aug;32(2):144-53
pubmed: 7972908
Radiat Res. 2002 Jun;157(6):700-10
pubmed: 12005550
Radiat Res. 2001 Mar;155(3):498-502
pubmed: 11182802
Cancer Sci. 2015 Mar;106(3):279-86
pubmed: 25580517
Int J Clin Oncol. 2020 Jan;25(1):43-50
pubmed: 31168726
J Radiat Res. 2019 Jan 1;60(1):29-36
pubmed: 30395286
Am J Clin Nutr. 2014 Jan;99(1):223S-230S
pubmed: 24284439
Cancer Lett. 2002 Dec 10;187(1-2):135-41
pubmed: 12359361
Appl Radiat Isot. 2020 Sep;163:109212
pubmed: 32561048
Sci Rep. 2018 Jan 17;8(1):988
pubmed: 29343841
Curr Cancer Drug Targets. 2019;19(11):863-876
pubmed: 31376820
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1121-9
pubmed: 8262837
Phys Med. 2021 Feb;82:306-320
pubmed: 33721790